ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
DIXDC1 Promotes Lymphatic Metastasis and Resistance to Cuproptosis in Bladder Cancer Through Mediating DLAT.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Lymph node metastasis (LN) represents a major clinical challenge in bladder cancer (BCa) and is associated with dismal prognosis; however, the underlying molecular drivers remain incompletely understood. Here, we demonstrate that DIX domain-containing protein 1 (DIXDC1) is significantly upregulated in LN-metastatic BCa tissues and is associated with unfavorable clinical outcomes. Functionally, DIXDC1 enhances BCa cell migration, invasion, proliferation, and lymph node dissemination in vivo. Mechanistically, DIXDC1 directly binds to dihydrolipoamide S-acetyltransferase (DLAT), a key enzyme in the tricarboxylic acid cycle and a central effector of cuproptosis. This interaction impedes ubiquitin-proteasome-mediated degradation of DLAT, thereby stabilizing DLAT protein levels. Through a DLAT-dependent pathway, DIXDC1 further augments the mRNA stability of the oncogenes NEK7 and CCNE2, fueling tumor progression. Importantly, DIXDC1 shields BCa cells from copper-induced DLAT oligomerization and confers marked resistance to Elesclomol-Cu (ES-Cu)-triggered cuproptosis. Depletion of DIXDC1 profoundly sensitizes tumors to cuproptosis in vivo. Collectively, our study unveils the DIXDC1-DLAT axis as a pivotal regulator that coordinately drives metastatic progression and suppresses copper-induced cell death, offering a promising therapeutic target for advanced BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.